Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q3 2015 Earnings Presentation
10 slides from Agilent Technologies's earnings presentation, 2015
Slide 1: Agilent Technologies Q3'15 Results Presentation
Agilent Technologies Q3’15 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company’s goals, priorities, revenues, demand, growth opportunities, customer service and innovation plans, new product introductions, financial condition, earning
Slide 3: Agilent Results Q3'15
Agilent Results Q3’15 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q3’15 Financial Metrics Q3 Headlines “Core” adjusted for NMR, Acquisitions, Divestitures, • Revenue at high end of guidance with strength in Pharma, and FX Diagnostics & Clinical, and Environm
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Strong revenue growth across all regions, and Instrumentation and Informatics for Analytical Laboratories boosted by logistics center catch-up of shipments. • Operating Margin for the quarter was 18.7%(1)(2), up 220 basis points over last year. • New Pr
Slide 5: Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) Analytical Laboratory • Core revenue growth strong across consumable Consumables and Services supplies, columns, sample prep and services. • Operating Margin in the quarter was 22.6%(1)(2) • New Offerings in Q3 fueling growth: • Launched the Agilent CrossLab Brand Promi
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) • Continued momentum across all DGG Businesses: Pathology, Genomics, and Nucleic Acid Manufacturing Dako, Genomics, and Nucleic Acid Solutions • Operating Margin for the quarter was 16.8%(1)(2), up 330 basis points over last year. • New Products and Platforms int
Slide 7: Growth in a $45B Market – Q3'15 Results by End Market
Growth in a $45B Market – Q3’15 Results by End Market Strength in Pharma, Diagnostics & Clinical, and Environmental & Forensics, Softness in Chemical & Energy Y/Y growth rates shown are unadjusted for currency, which Agilent Revenue by End Market (1) had an overall negative 7% impact across Agilent
Slide 8: Profitable Growth Plan
Agilent Profitable Growth Plan Recent Actions On-Track to Deliver “Agile Agilent” Program Benefits • Multi-year program to increase efficiency and customer focus • Initiatives have delivered $35M savings to date, on track to lower costs by $50M in FY15 • New business group structure & portfolio •
Slide 9: Strategy to Win
Agilent Strategy to Win Creating shareholder value Accelerate Organic Growth • Focus on sustaining share growth within the core Analytical Lab • Continue to bring innovative new offerings to the market • Expand lab-wide services & consumables with a differentiated customer experience • Leverage An
Slide 10: Q4'15 and FY15 Guidance and Forward-looking Considerations
Q4’15 and FY15 Guidance and Forward-looking Considerations Based on July 31, 2015 Exchange Rates FY15 Guidance FY15 • Revenue: $4.03B - $4.05B; growth at mid-point 6.6% core(4), flat FY14 Guidance at reported (1) (-0.5% NMR, 0% M&A, -6.1% FX) Actual (2) mid-point (1)(2) • EPS: $1.68 - $1.72, assumed